Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zometa in locally advanced breast cancer
NCT00242203Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2002
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zoledronic acid in breast cancer (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Clearance of bone marrow micrometastases and Chemotherapy-induced loss of bone mineral density. Started Oct 2002; status: completed.
02
Drugs
zoledronic acid
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00242203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242203.